Barriers to medical cannabis treatment, the rights of prescribed patients at work and encounters with police will be debated at a London symposium next month.
The Cannabis Health Symposium will take place at Conway Hall on 26th November, bringing together clinicians, researchers, regulators, and patient advocates. Its programme includes discussions on access through the National Health Service (NHS), standards of care in private clinics and a closing patient round-table.
The event, which launched last year, will be one of two organised by medical cannabis publication Cannabis Health, with an earlier symposium taking place in Frankfurt on 4th November.
Sarah Sinclair, editor of Cannabis Health and host of the London event, said: “Medical cannabis policy is being written right now, and too often without the clinicians who prescribe it or the patients who depend on it. These symposiums put those voices in the same room as the regulators and the industry, creating a space for open conversations and much-needed education.”
The London programme, featuring 20 sessions and 5 panel debates, will address practical difficulties that can continue long after a patient receives a prescription.
Professor Kim Wolff, director of King’s Forensics at King’s College London, will discuss workplace issues including drug testing, fitness for work and reasonable adjustments. Richard List, of the Association of Police Controlled Drug Liaison Officers, will present guidance on patients’ rights and responsibilities when dealing with police.
A separate workshop led by Alex Fraser, founder of Patient Protect, will examine discrimination involving policing, employment, housing and healthcare, drawing on the organisation’s casework.
Sessions will examine NHS prescribing pathways and how clinics meet Care Quality Commission expectations. Professor Trevor Jones, co-chair of the UK Cannabinoid Research and Development Group, will discuss the UK’s approach to cannabinoid research.
Professor David Nutt, of Imperial College London and Drug Science, will join a debate on how evidence from patients receiving treatment in everyday practice should be considered alongside randomised controlled trials, which compare treatments in randomly assigned groups.
Other sessions will examine mental health risks, attention deficit hyperactivity disorder and autism, women’s health and pain. Tilray Medical will present treatment data from 106 cases, while 4C Labs will discuss research into adulteration in the illicit market.
The day will close with patients describing their experiences of accessing and using cannabis medicines, including how communication with prescribers can improve their care.
The Frankfurt symposium, at Mainhaus Stadthotel, will examine remote consultations and mail-order dispensing, including the implications of proposed restrictions for patients’ access to treatment.
Its programme also covers chronic pain, women’s health and endometriosis, alongside a debate on whether Europe needs a shared framework for the pharmaceutical quality of cannabis medicines.
Tobias Bosse, chief commercial officer at Grünhorn Group and a speaker in the telemedicine debate, said: “Banning telemedicine doesn’t solve anything. It just pushes patients back to the black market. Proportionate quality standards are the better path to both patient safety and access to therapy.”
Tickets and full listings for both events are available from the organisers, leafie readers can get 10% off the ticket price with code LEAFIE10.
Cover image source: Conway Hall

















